Sign up Australia
Proactive Investors - Run By Investors For Investors

Indivior's dive puts it into buying territory, Numis believes

In the last six weeks or so, the share price of Indivior has plunged from 493p to 306p and that's a level at which Numis thinks the upside risk outweighs the downside
Generic versions of indivior's blockbuster drug for the treatment of opioid addiction are waiting in the wings

The Indivior PLC (LON:INDV) share price has fallen 20% over the last month and is now in buying territory, according to Numis Securities.

The stock has been hit by the continued threat of Indian outfit Dr Reddy producing a generic version of Suboxone, Indivior’s treatment for opioid addiction, and disappointing uptake levels for Sublocade, its injectable treatment of moderate-to-severe opioid use disorder.

READ: Indivior takes another hit as it warns of further impact from launch of Suboxone copycat

Sublocade was launched in February and although management has spoken of “some friction in the new distribution and reimbursement model” in the US, Numis was encouraged by the level at which sales were running at the end of the second quarter.

“We do not believe the company is completely through legal volatility with Dr Reddy's appeal of the injunction ongoing and Alvogen poised to gain FDA approval at some point,” Numis admitted, but nevertheless it thinks the reaction to the Sublocade launch, at least, has been overdone.

“We still forecast generic film in H2 and significant loss of share in FY19 and see any additional US cash flow from film as an upside surprise,” it said, as it upgraded the stock to ‘buy’ from ‘add’.

The broker says its 380p price target, based on a discounted cash flow model, is well supported.

Shares in Indivior currently trade at around 309p, having recovered from 266.5p on Wednesday, July 11, when it lowered full-year guidance.

FDA decision on RBP-7000 schizophrenia treatment ​due this weekend

Indivior has an injunction on Dr Reddy, preventing the Indian company from selling a generic version of Suboxone in the US, and Numis does not think the generic drugs maker will succeed in removing the injunction, although a long legal fight looks likely.

Another potential bull catalyst for the shares is approval by the US Food and Drugs Administration (FDA) of RBP-7000, its schizophrenia treatment; Numis said a decision from the FDA is expected this weekend.

As for the bear case, Numis now sees Alvogen as the biggest threat to Indivior’s future.

So far as Indivior is aware, the FDA has not yet granted tentative or final marketing authorisation to Alvogen's generic buprenorphine/naloxone film product; were it to do so, Alvogen, would be able to market its generic buprenorphine/naloxone film product in the US, but any market launch by Alvogen before a ruling on appeal would be on an "at risk" basis because Indivior would have a claim for damages against Alvogen if Indivior ultimately prevails on appeal.

“In light of the published opinion from the District Court of New Jersey, we might expect Alvogen to be better prepared than Dr Reddy’s and to be able to provide a more compelling case on the reason(s) why a potential "at-risk" launch should be allowed and why an injunction should not be granted,” Numis cautioned.


View full INDV profile View Profile

Indivior Timeline

Related Articles

July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson
September 28 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use